We assign Siegfried a Medium Morningstar Uncertainty Rating. Its business is relatively stable, with high switching costs and good visibility due to long-term customer contracts. However, small ...

D Molecular Therapeutics is undervalued, with its lead candidate 4D-150 showing potential. Click here to find out why I rate FDMT stock a Buy.

Finding the right lubricant for the right purpose is a task that is often extremely important in industry. Not only to reduce ...

The company raised $200 million after early findings hinted its therapy could be more potent than others like it, including Sarepta Therapeutics’ Elevidys.

Solid Biosciences (SLDB) stock surges after strong Phase 1/2 data for its Duchenne therapy SGT-003. Read more here.

Solid Biosciences has surged back into the Duchenne muscular dystrophy (DMD) gene therapy race. | Solid Biosciences has ...

Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company focused on developing precision medicines for ...

Service utilization is the biggest factor behind spending variation, with prices, disease prevalence, and demographics ...

As of December 31, 2024, the Company had cash and cash equivalents in the amount of $15.6 million, compared to $5.3 million ...

The Tuesday decision is the latest in a string of court orders blocking or slowing President Donald Trump’s early actions.

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

A consumer fact sheet by the U.S. Environmental Protection ... state rules showed issues with PFOA in one of the system's ...